Clomipramine Hcl Cas No. 17321-77-6

Clomipramine is used to treat obsessive compulsive disorder (OCD). It helps decrease persistent/unwanted thoughts (obsessions), and it helps reduce the urge to perform repeated tasks (compulsions such as hand-washing, counting, checking) that interfere with daily living.



Active Pharmaceuticals Ingredients Manufacturers

Taj Pharmaceuticals Ltd. **Clomipramine Hcl** CAS No.: 17321-77-6

Synonym:

Anafranil hydrochloride,3-Chloro-10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride CAS Number: 17321-77-6


Linear Formula: C19H23ClN2 HCl Molecular Weight: 351.31 EC Number: 241-344-3 MDL number: MFCD00069234

Description

Biochem/physiol Actions Tricyclic antidepressant; inhibits serotonin and norepinephrine transporters.

Properties

Assay: 98% (HPLC) Form: Powder Color: White to off-white Solubility: H2O: soluble25 mg/mL 0.1 M HCl: soluble



• મદ્દા

C19H23CIN2 • HCl

MW = 351.31

Gene Information: Research your gene in Your Favorite Gene powered by Ingenuity human ... HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR4(3360), HTR5A(3361), HTR5B(645694), HTR6(3362), HTR7(3363)

DOSAGE

Initial doses are usually 25 mg 2 or 3 times daily or 75 mg once daily in slow released form. The dose may be increased in regular intervals (the usual dose per day is 100 to 225 mg). Doses up to 300 mg may be used, but these are associated with an increased risk of seizures. This medication may be taken with food to prevent stomach upset.

In hospitalized patients initial intramuscular injections and very slow intravenous infusions can be used, but the risk of hypotension and seizures may be increased with parenteral drug use. The advantage is that the onset of action may be faster.

Usually, clomipramine needs some weeks to reach its maximum effects and needs to be given as longterm treatment, sometimes for life (narcolepsy). Sometimes, in patients with narcolepsy the full effect of clomipramine is not sufficient. In these cases treatment with clomipramine should be terminated gradually and a commonly used central stimulant (e.g. modafinil, methylphenidate or methamphetamine) tried instead.

Clomipramine is not able to elevate the mood of non-depressive persons and any unindicated use may be dangerous.

Dosage should be individualized according to the requirements of each patient. Treatment should be initiated at the lowest recommended dose and increased gradually, noting carefully the clinical response and any evidence of intolerance. During the initial dose titration phase, the total daily dose of clomipramine should be divided and served with meals to reduce gastrointestinal side-effects.

Endocrine:

Weight loss, breast enlargement and galactorrhea in the female, inappropriate antidiuretic hormone (ADH) secretion syndrome, gynecomastia in the male, changes in blood sugar levels, increase in prolactin levels, menstrual irregularity.



Taj Group of Companies **TAJ PHARMACEUTICALS LIMITED** "Working for human race"

www.tajpharma.com www.tajagroproducts.com www.tajfordoctors.com

PAGE-1

Taj Pharmaceuticals Ltd. Clomipramine Hcl CAS No. : 17321-77-6





Allergic or Toxic:

Allergic skin reactions (skin rash, urticaria), photosensitization, pruritus, edema, drug fever.

Withdrawal Symptoms:

Abrupt cessation of treatment with tricyclic antidepressants after prolonged administration may occasionally

Endocrine:

Weight loss, breast enlargement and galactorrhea in the female, inappropriate antidiuretic hormone (ADH) secretion syndrome, gynecomastia in the male, changes in blood sugar levels, increase in prolactin levels, menstrual irregularity.

INTERACTION

Tricyclic antidepressants, such as clomipramine, may interact with many other drugs. Patients should inform their physicians about all other drugs they are taking before starting treatment.

Clomipramine may intensify the effects of other drugs that act on serotonin levels, possibly producing serotonin syndrome, a rare but dangerous condition with fever, sweating, tremors, and changes in mental state. Drugs that may interact this way include other antidepressants, especially selective serotonin re-uptake inhibitor (SSRI) drugs and monoamine oxidase (MAO) inhibitors. These drugs should not be taken within two weeks of taking clomipramine. Other drugs to avoid include lithium, alprazolam(Xanax), fenfluramine (Pondimin), amphetamine, dextromethorphan (used in cough suppressants), meperidine (Demerol), and tramadol (Ultram).

Tricyclic drugs may intensify the effects of other drugs causing sedation, including alcohol, barbiturates, narcotic pain medications, minor tranquilizers, and antihistamines. Tricyclics may cause excessive reductions of blood pressure in patients taking blood pressure medicine, especially on arising or standing up. Conversely, these drugs may interfere with the pressure-reducing effects of certain other blood pressure medicines and may necessitate an adjustment in dosage. Tricyclics may interact with thyroid medications to produce abnormalities of heart rhythm. Concurrent use of tricyclic antidepressants with other psychiatric medicines may result in intensification of certain side effects.

Certain drugs may interfere with the elimination of tricyclic antidepressants from the body, causing higher blood levels and increased side effects. This effect may occur with cimetidine (Tagamet), other antidepressants, methylphenidate(Ritalin, Concerta), and some antipsychotic medications.

PHARMALOGY

Clomipramine is the 3-chloro derivative of imipramine. Clomipramine is a strong, but not completely selective serotonin reuptake inhibitor (SSRI), as the primary active metabolite desmethylclomipramine acts preferably as norepinephrine reuptake inhibitor. Other hydroxy-metabolites are also active. a 1 receptor blockage and β receptor downregulation as well as postsynaptic antagonism on histamine H1 receptors and dopamine receptors have been noted.

As with other tricyclics, downregulation of NMDA receptors may also account for its effects.

Clomipramine has the disadvantage of a higher incidence of seizures than seen with other tricyclic antidepressants (up to a dose of 250 mg daily in 0,5 %, more than 300 mg in 2 %).

Clomipramine is a tricyclic agent with both antidepressant and antiobsessional properties. Like other tricyclics, clomipramine inhibits norepinephrine and serotonin uptake into central nerve terminals, possibly by blocking the membrane-pump of neurons, thereby increasing the concentration of transmitter monoamines at receptor sites. Clomipramine is presumed to influence depression and obsessive and compulsive behaviour through its effects on serotonergic neurotransmission.

PAGE-2



Taj Group of Companies TAJ PHARMACEUTICALS LIMITED "Working for human race"

www.tajpharmaceuticals.com www.tajagroproducts.com www.tajfordoctors.com

Taj Pharmaceuticals Ltd. Clomipramine Hcl CAS No. : 17321-77-6

The actual neurochemical mechanism is unknown, but clomipramine's capacity to inhibit serotonin reuptake is thought to be important. Clomipramine appears to have a mild sedative effect which may be helpful in alleviating the anxiety component often accompanying depression.

As with other tricyclic compounds, clomipramine possesses anticholinergic properties which are responsible for some of its side effects. It also has weak antihistamine and antiserotonin properties, lowers the convulsive threshold, potentiates the effect of norepinephrine and other drugs acting on the CNS, has a quinidine-like effect on the heart and may impair cardiac conduction.

The action of clomipramine on the human EEG is one of desynchronization. It causes a persistent increase in the frequency of shifts into stage I sleep and produces marked reduction or suppression of rapid eye movement sleep (REM or paradoxical sleep) with partial recovery within 3 to 4 weeks and a rebound after drug withdrawal which appears to last approximately the same time. In normal human volunteers tricyclic antidepressants tend to produce a sedative effect accompanied by atropine-like symptoms and may produce some difficulty in concentrating and thinking.

Absorption is rapid and complete after oral administration in man. Plasma levels usually peak 2 hours after dosage but much individual variation occurs. The plasma half-life after a single oral dose is approximately 21 hours. After 28 days of oral administration to patients in a daily dosage of 75 mg, plasma concentrations of clomipramine ranged from 17 to 70 ng/mL (mean=35.7 ng/mL). The concentration of the active metabolite, desmethylclomipramine, was about twice as high.

Binding to serum proteins at 96 to 97% is very high and is practically concentration-independent within the therapeutic range. Clomipramine has a volume of distribution of approximately 12 L/kg bodyweight.

Clomipramine is extensively metabolized in the body with hydroxylation, demethylation and N-oxidation being the quantitatively more important routes of metabolism.

Owing to the lower clearance of clomipramine in plasma, elderly patients require lower doses of clomipramine than patients in younger age groups.

As expected, the metabolites of clomipramine are quite similar to those of imipramine, all retaining the benzazepine structure. Two-thirds of clomipramine is excreted in the form of water-soluble conjugates in the urine and approximately one-third in the feces. After a 25 mg radiolabelled dose of clomipramine in 2 subjects, the urinary recoveries of clomipramine and desmethylclomipramine were about 2% and 0.5% of the total radioactivity, respectively.

Note /Government Notification: These chemicals are designated as those that are used in the manufacture of the controlled substances and are important to the manufacture of the substances. For any (Control Substance) products Import and Export *** subjected to your country government laws /control substance ACT. Information: The information on this web page is provided to help you to work safely, but it is intended to be an overview of hazards, not a replacement for a full Material Safety Data Sheet (MSDS). MSDS forms can be downloaded from the web sites of many chemical suppliers. ,also that the information on the PTCL Safety web site, where this page was hosted, has been copied onto many other sites, often without permission. If you have any doubts about the veracity of the information that you are viewing, or have any queries, please check the URL that your web browser displays for this page. If the URL begins "www.tajapi.com/www/Denatonium Benzoate.htm/" the page is maintained by the Safety Officer in Physical Chemistry at Oxford University. If not, this page is a copy made by some other person and we have no responsibility for it.

The Controlled Substances Act (CSA) was enacted into law by the Congress of the United States as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970.[1] The CSA is the federal U.S. drug policy under which the manufacture, importation, possession, use and distribution of certain substances is regulated. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs

This document plus the full buyer/ prescribing information, prepared for health professionals can be found at: http://www.tajapi.com or by contacting the sponsor, Taj Pharmaceuticals Limited., at: 91 022 30601000. This leaflet was prepared by Taj Pharmaceuticals Limited, Mumbai (India). MPSTJ278 Last revised: 29 August 2009



PHARMACEUTICALS[№]

ACTIVE PHARMACEUTICAL INGREDIENTS

www.tajpharmaceuticals.com www.tajagroproducts.com www.tajfordoctors.com

PAGE-3